rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-271-275rsp-3175Research ArticleПРОБЛЕМЫ РЕВМАТОЛОГИИ В ПЕРИОД ПАНДЕМИИ КОРОНОВИРУСНОЙ БОЛЕЗНИ 2019PROBLEMS OF RHEUMATOLOGY DURING THE 2019 CORONAVIRUS PANDEMICАутоантитела при коронавирусной инфекции (COVID-19): клиническое наблюдениеAutoantibodies and SARS-CoV-2 infection: A case reportКаленчицТ. И.KalenchicT. I.

220116, Минск, проспект Дзержинского, 83

КабакС. Л.KabakS. L.

220116, Минск, проспект Дзержинского, 83

220116, Minsk, Dzerzhinskogo avenue, 83 

КореневскаяИ. В.KorenevskayaI. V.

220037, Минск, Уральская ул., 5

220037, Minsk, Uralskaya str., 5

УО «Белорусский государственный медицинский университет»БеларусьBelarussian State Medical UniversityBelarusУЗ «6-я городская клиническая больница»Беларусь6th City Clinical HospitalBelarus202209072022603271275Copyright © Каленчиц Т.И., Кабак С.Л., Кореневская И.В., 20222022Каленчиц Т.И., Кабак С.Л., Кореневская И.В.Kalenchic T.I., Kabak S.L., Korenevskaya I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3175

В статье представлен клинический случай COVID-19 пневмонии у пациента, имевшего лабораторные признаки цитокинового шторма (многократное превышение референсных значений С-реактивного белка, ферритина и D-димера) в сочетании с повышением уровня аутоантител (антифосфолипидных антител (аФЛ) и антител к циклическому цитруллинированному пептиду). При этом использование компьютерной томографии с контрастированием и ультразвукового исследования не позволило визуализировать присутствие тромбов в ветвях легочных артерий и венах нижних конечностей. Через 3 месяца после завершения стационарного лечения у пациента сохранялось повышение уровня аФЛ и D-димера. В статье обсуждается вопрос о возможной связи инфицирования вирусом SARS-CoV-2 с аутоиммунными заболеваниями. 

The article describes a COVID-19 patient with several biomarkers of systemic cytokine storm (including multiple excess over the reference values of C-reactive protein, ferritin and D-dimer) and increased level of autoantibodies (aPL and anti-CCP). At the same time contrast-enhanced CT and US failed to detect pulmonary embolism or lower limb deep vein thrombosis. Three months after discharge from the hospital, a high level of antiphospholipid antibodies and D-dimer remained. The relationship between infection with SARS-CoV-2 and autoimmunity has been discussed. 

COVID-19аутоимунные болезниантитела к циклическому цитруллинированному пептидуантитела к кардиолипинуантитела к β2-гликопротеинуCOVID-19autoimmune diseasesanti-cyclic citrullinated peptide antibodiesanti-cardiolipin antibodiesanti-β(2)-glycoprotein antibodiesReferencesSacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907. doi: 10.1111/cts.12953Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907. doi: 10.1111/cts.12953Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. 2020;13(6):1077-1086. doi: 10.1111/cts.12805Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. 2020;13(6):1077-1086. doi: 10.1111/cts.12805Gao ZW, Zhang HZ, Liu C, Dong K. Autoantibodies in COVID19: frequency and function. Autoimmun Rev. 2021;20(3):102754. doi: 10.1016/j.autrev.2021.102754Gao ZW, Zhang HZ, Liu C, Dong K. Autoantibodies in COVID19: frequency and function. Autoimmun Rev. 2021;20(3):102754. doi: 10.1016/j.autrev.2021.102754Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med. 2020;383(3):288-290. doi: 10.1056/NEJMc2013656Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med. 2020;383(3):288-290. doi: 10.1056/NEJMc2013656Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. doi: 10.14412/1995-4484-2014-56-71Reshetnyak TM. Antiphospholipid syndrome: Diagnosis and clinical manifestations (a lecture). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.). doi: 10.14412/1995-4484-2014-56-71Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, AlonsoMuñoz J, Del Toro-Cervera J, di Natale M, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020;192:113- 115. doi: 10.1016/j.thromres.2020.05.017Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, AlonsoMuñoz J, Del Toro-Cervera J, di Natale M, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020;192:113- 115. doi: 10.1016/j.thromres.2020.05.017Полушин ЮС, Гаврилова ЕГ, Шлык ИВ, Лапин СВ, Ткаченко ОЮ. Катастрофический антифосфолипидный синдром при COVID-19. Вестник анестезиологии и реаниматологии. 2021;18(1):17-26. doi: 10.21292/2078-5658-2021-18-1-17-26Polushin YuS, Gavrilova EG, Shlyk IV, Lapin SV, Tkachenko ОYu. Catastrophic antiphospholipid COVID19 syndrome. Messenger of Anesthesiology and Resuscitation. 2021; 18(1):17-26 (In Russ.). doi: 10.21292/2078-5658-2021-18-1-17-26Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-19. Clin Transl Sci. 2021;14(5): 1625-1626. doi: 10.1111/cts.13036Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-19. Clin Transl Sci. 2021;14(5): 1625-1626. doi: 10.1111/cts.13036Lingel H, Meltendorf S, Billing U, Thurm C, Vogel K, Majer C, et al. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun. 2021;122:102682. doi: 10.1016/j.jaut.2021.102682Lingel H, Meltendorf S, Billing U, Thurm C, Vogel K, Majer C, et al. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun. 2021;122:102682. doi: 10.1016/j.jaut.2021.102682Derksen VFAM, Kissel T, Lamers-Karnebeek FBG, van der Bijl AE, Venhuizen AC, Huizinga TWJ, et al. Onset of rheumatoid arthritis after COVID-19: Coincidence or connected? Ann Rheum Dis. 2021 Mar 1:annrheumdis-2021-219859. doi: 10.1136/annrheumdis-2021-219859Derksen VFAM, Kissel T, Lamers-Karnebeek FBG, van der Bijl AE, Venhuizen AC, Huizinga TWJ, et al. Onset of rheumatoid arthritis after COVID-19: Coincidence or connected? Ann Rheum Dis. 2021 Mar 1:annrheumdis-2021-219859. doi: 10.1136/annrheumdis-2021-219859Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81(3):357-371. doi: 10.1016/j.jinf.2020.06.067Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81(3):357-371. doi: 10.1016/j.jinf.2020.06.067Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al.; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15): 1488-1494. doi: 10.1001/jama.2020.3204Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al.; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15): 1488-1494. doi: 10.1001/jama.2020.3204Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al.; COVID-19 Global Rheumatology Alliance Steering Committee. Rheumatic disease and COVID-19: Initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020;2(5):e250-e253. doi: 10.1016/S2665-9913(20)30095-3Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al.; COVID-19 Global Rheumatology Alliance Steering Committee. Rheumatic disease and COVID-19: Initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020;2(5):e250-e253. doi: 10.1016/S2665-9913(20)30095-3Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. doi: 10.47360/1995-4484-2021-5-30Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021;59(1): 5-30 (In Russ.). doi: 10.47360/1995-4484-2021-5-30Tripathy A, Swain N, Gupta B. The COVID-19 pandemic: An increased risk of rheumatoid arthritis. Future Virol. 2021 Jun:10.2217/fvl-2020-0393. doi: 10.2217/fvl-2020-0393Tripathy A, Swain N, Gupta B. The COVID-19 pandemic: An increased risk of rheumatoid arthritis. Future Virol. 2021 Jun:10.2217/fvl-2020-0393. doi: 10.2217/fvl-2020-0393Lima I, Santiago M. Antibodies against cyclic citrullinated peptides in infectious diseases – A systematic review. Clin Rheumatol. 2010;29(12):1345-1351. doi: 10.1007/s10067-010-1544-xLima I, Santiago M. Antibodies against cyclic citrullinated peptides in infectious diseases – A systematic review. Clin Rheumatol. 2010;29(12):1345-1351. doi: 10.1007/s10067-010-1544-xSarkar M, Madabhavi IV, Quy PN, Govindagoudar MB. COVID19 and coagulopathy. Clin Respir J. 2021;15(12):1259-1274. doi: 10.1111/crj.13438Sarkar M, Madabhavi IV, Quy PN, Govindagoudar MB. COVID19 and coagulopathy. Clin Respir J. 2021;15(12):1259-1274. doi: 10.1111/crj.13438Shabaka A, Gruss E, Landaluce-Triska E, Gallego-Valcarce E, Cases-Corona C, Ocaña J, et al. Late thrombotic complications after SARS-CoV-2 infection in hemodialysis patients. Hemodial Int. 2021;25(4):507-514. doi: 10.1111/hdi.12935Shabaka A, Gruss E, Landaluce-Triska E, Gallego-Valcarce E, Cases-Corona C, Ocaña J, et al. Late thrombotic complications after SARS-CoV-2 infection in hemodialysis patients. Hemodial Int. 2021;25(4):507-514. doi: 10.1111/hdi.12935Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382(17):e38. doi: 10.1056/NEJMc2007575Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382(17):e38. doi: 10.1056/NEJMc2007575Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with COVID-19. J Thromb Haemost. 2020;18(8):2064-2065. doi: 10.1111/jth.14867Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with COVID-19. J Thromb Haemost. 2020;18(8):2064-2065. doi: 10.1111/jth.14867Mendoza-Pinto C, García-Carrasco M, Cervera R. Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant). Curr Rheumatol Rep. 2018;20(10):62. doi: 10.1007/s11926-018-0773-xMendoza-Pinto C, García-Carrasco M, Cervera R. Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant). Curr Rheumatol Rep. 2018;20(10):62. doi: 10.1007/s11926-018-0773-xBorghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, et al.. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol. 2020;11:584241. doi: 10.3389/fimmu.2020.584241Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, et al.. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol. 2020;11:584241. doi: 10.3389/fimmu.2020.584241Решетняк ТМ, Чельдиева ФА, Нурбаева КС, Лила АМ, Насонов ЕЛ. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;(4):4-21. doi: 10.25555/THR.2020.4.0940Reshetnyak TM, Cheldieva FA, Nurbayeva KS, Lila AM, Nasonov EL. Antiphospholipid syndrome: Diagnosis, development, therapy. Tromboz, gemostaz i reologia. 2020;(4):4-21 (In Russ.). doi: 10.25555/THR.2020.4.0940

The authors declare that there are no conflicts of interest present.